Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
Reza Shojaei, Executive Leader, Strategic Growth Advisor in Health and Biopharma, shared on LinkedIn:
”Are Hemoglobin Oxygen Carriers (HBOCs) a breakthrough waiting to happen, or just hype?
What if we could deliver oxygen without relying on blood donors, refrigeration, or blood typing?
That’s the bold promise of Hemoglobin Oxygen Carriers (HBOCs), sometimes called “artificial blood.”
Approved in South Africa, tested in Japan, funded by the U.S. military, and eyed for organ preservation in Europe… yet still viewed with caution by regulators.
So, are HBOCs a breakthrough waiting to happen, or just hype?’
In this newsletter edition, we explore:
- Where HBOCs stand today
- Their advantages and safety challenges
- Whether they can truly replace blood donation
- What the global market looks like in 2025
- If they’re viable for low- and middle-income countries”
Read the full Blood and Plasma Pulse newsletter edition here.
Stay updated on the emerging in the field of hematology with Hemostasis Today.
-
Dec 10, 2025, 17:22In the Fight for Hematology: Adetokunbo O’s Reflections from ASH25
-
Dec 10, 2025, 17:11Driving Innovation in Rare Blood Disorders: Jeff Schaffnit’s ASH 2025 Perspective
-
Dec 10, 2025, 16:37Arthur Allen – The New President-Elect of the Anticoagulation Forum Board of Directors
-
Dec 10, 2025, 16:29Matthew D Neal: An Oasis in the Platelet Desert?
-
Dec 10, 2025, 16:14Yashpal Singh Rawat: Fortis Memorial Research Institute Made Its Positive Mark at ASH
-
Dec 10, 2025, 14:57Elvira Grandone Announces the 1st ThrombUS+ Data Challenge
-
Dec 10, 2025, 14:18Love Preet Kalra on A Paradigm Shift in ICH
-
Dec 10, 2025, 13:37Aakanksha A: A Highlight of the Week Was Presenting Our ASH Poster
-
Dec 9, 2025, 23:37Thomas Reiser: Renew Your ISTH Membership for 2025